InvestorsHub Logo
Followers 2
Posts 1257
Boards Moderated 0
Alias Born 07/16/2006

Re: None

Friday, 09/17/2021 2:56:44 PM

Friday, September 17, 2021 2:56:44 PM

Post# of 258
AZN..Results from the large, randomized COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with IMFINZI® (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to IMFINZI alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRVS News